Example 1

The Patient Who Has Failed Everything for Depression

One of the most difficult situations in outpatient psychiatry: a patient with MDD and GAD who is overweight and hasn't responded to two SSRIs or two SNRIs. The question is what to do next. Here's how AskCarlat AI handled it.


AskCarlat AI
Clinician
Pt is overweight and failed 2 SSRIs and SNRIs and has MDD and GAD uncontrolled — what to try next?
AskCarlat AI

For the overweight patient who has not responded to two SSRIs and two SNRIs with persistent MDD + GAD, Carlat's guidance suggests the following next steps.

1. Augment with a GAD-focused agent that is weight-neutral
Agent Why it fits Typical dosing (Carlat) Weight impact
Buspirone FDA-approved for GAD; no sedation, no sexual side-effects 15–20 mg BID or TID, titrated up as needed No appreciable weight gain
Hydroxyzine (PRN) FDA-approved for GAD; useful when anxiety spikes; short-acting 0.5 mg/kg PO q4–6h PRN Minimal weight impact
Silexan (lavender extract) OTC product; effect sizes (0.5–0.9) that exceed many SSRIs/SNRIs 80–160 mg PO daily (at night) Weight-neutral
2. Antidepressant augmentation for the depressive component
Option Rationale (Carlat) Typical dose Weight impact
Bupropion (if not yet tried) Dopaminergic/noradrenergic mechanism; modest antidepressant effect Start 150 mg QD → 300 mg QD Weight-neutral or modest loss
Quetiapine (low-dose augmentation) Large effect size for GAD when anxiety co-exists with depression 25–50 mg PO nightly Weight gain risk — use only if benefits outweigh this
3. If still treatment-resistant, move to neuromodulation

Repetitive TMS was FDA-cleared for patients who have failed 1–4 antidepressant trials. Carlat emphasizes response rates are higher when TMS is used earlier in the resistance ladder. The accelerated "SAINT" protocol achieved remission rates of 70–90% in highly resistant cohorts (FDA-cleared September 2023).

Carlat note: Mirtazapine and quetiapine are effective but carry significant weight gain risk — avoid or use with informed consent in overweight patients.
Sources: How to Choose an Antidepressant · Treatment-Resistant Depression · Special Report: Refractory Anxiety Disorders Part 2
Example 2 of 3

Bipolar Depression, Alcohol Use Disorder, and Suicidality — All at Once

Complex comorbidities are the norm in psychiatry, not the exception. This clinician was managing a young woman with the triple challenge of bipolar depression, an active alcohol use disorder, and suicidality. The response shows how 23 years of Carlat content gets synthesized into a prioritized, usable plan.


AskCarlat AI
Clinician
How should bipolar depression be treated in a young woman with comorbid AUD and suicidality?
AskCarlat AI
1. Core pharmacologic strategy
Goal Medication Rationale (Carlat) Starting dose & titration
Stabilize mood + reduce suicide risk Lithium Proven efficacy in both manic and depressive phases; specifically lowers suicide risk in bipolar disorder 300 mg BID → titrate to 0.6–0.8 mEq/L
Dual benefit: mood + AUD Valproate (Depakote) In a 6-month trial, valproate reduced heavy drinking when added to lithium — strong evidence for bipolar + AUD 250 mg BID → 50–125 µg/mL serum level
Bipolar depression — FDA-approved options Lurasidone (Latuda) Effective and better metabolically tolerated than quetiapine 20 mg QD → up to 120 mg QD

 Cariprazine (Vraylar) Effective with lower metabolic risk 1.5 mg QD → up to 6 mg QD
2. Addressing the alcohol use disorder
Medication Rationale Interaction notes
Naltrexone Evidence of benefit when combined with sertraline in co-occurring MDD + AUD Avoid if patient is on opioids; check renal function
Acamprosate Reduces cravings and supports abstinence; no hepatic metabolism Safe with valproate; monitor renal function
Key Carlat point: Antidepressants should only be added once a mood stabilizer or antipsychotic is already established. SSRIs and SNRIs carry a higher risk of inducing mania or rapid cycling in bipolar disorder when used alone.
Sources: How to Treat Bipolar Depression · Bipolar Disorder and Addiction: Untangling a Complex Overlap · Do Antidepressants Have Any Role in Acute Bipolar Depression?
Example 3 of 3

Tapering Xanax After Years of Daily Use

Benzodiazepine deprescribing is one of the most common and most anxiety-inducing tasks in clinical psychiatry — for both the clinician and the patient. This clinician needed a concrete taper plan for a patient on 1 mg of alprazolam three times daily. The AI delivered a step-by-step protocol grounded in Carlat's benzo-tapering framework, including the nuances of converting to a long-acting agent first.


AskCarlat AI
Clinician
How do I safely taper a patient off 1 mg of Xanax TID?
AskCarlat AI

Alprazolam (Xanax) — safe tapering plan for a patient on 1 mg TID (3 mg/day)

Step 1: Convert to a long-acting benzodiazepine first

The Carlat "How to Get Off Benzos Safely" article recommends switching a short-acting drug (alprazolam or lorazepam) to a long-acting agent before tapering. Clonazepam is preferred: its longer half-life (~18–30 hours) smooths withdrawal, and its slower onset is less reinforcing.

Conversion Clonazepam dose Alprazolam equivalent Rationale
Starting point 0.5 mg BID (1 mg/day) ≈ 1 mg TID alprazolam Steady plasma level reduces breakthrough anxiety and cravings
Stabilize Hold at 0.5 mg BID for 1–2 weeks — Confirm tolerance before beginning taper
Step 2: Hyperbolic taper (Carlat "How to Stop a Psychiatric Med" protocol)

Reduce by 10–20% of the current dose, then use smaller absolute reductions as the dose gets low. This mirrors Ashton Manual principles validated in Carlat's tapering series.

Phase Clonazepam dose Duration Notes
Phase 1 0.5 mg BID → 0.5 mg AM + 0.25 mg PM 2–4 weeks First reduction (~25%). Pause longer if withdrawal symptoms emerge.
Phase 2 0.5 mg AM + 0.25 mg PM → 0.25 mg BID 2–4 weeks Another 25% of current dose. Slower pace now — absolute reductions feel larger.
Phase 3 0.25 mg BID → 0.25 mg QD 3–4 weeks Consider liquid formulation or pill-cutter for precise dosing.
Phase 4 0.25 mg QD → 0.125 mg QD → discontinue 4–6 weeks Final stretch. Very slow reductions. Use 0.5 mg/mL liquid if available.
Carlat clinical tip: If the patient experiences significant anxiety, insomnia, or tremor at any phase, hold the current dose for 2 additional weeks before reducing again. There is no prize for speed — a slower taper dramatically improves completion rates.
Sources: How to Get Off Benzos Safely · Alprazolam (Xanax) Fact Sheet for General Psychiatry · Switching Antidepressants: Direct Switch vs. Cross Taper